Clinical research of N-acetylcysteine in alleviating hepatorenal damage caused by chemotherapeutic drugs in elderly patients
10.3760/cma.j.issn.0254-9026.2009.08.016
- VernacularTitle:N-乙酰半胱氨酸防治老年患者化疗药物性肝肾损害的临床研究
- Author:
Juanjuan LI
;
Tongqiang LIU
;
Keqing QIAN
;
Youliang WANG
;
Haiyan MIN
;
Xi FENG
- Publication Type:Journal Article
- Keywords:
Acetylcysteine;
Drug therapy,combination;
Hepatic insufficiency;
Renalinsufficiency
- From:
Chinese Journal of Geriatrics
2009;28(8):668-670
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the effect of N-acetylcysteine (NAC) on alleviating hepatorenal damage caused by combined chemotherapy using cisplatin-based regiments in elderly patients. MethodsAll 40 elderly patients with malignant tumors were randomly divided into AB and BA group in cross-over pattern. In AB group, combination of chemotherapy and NAC was administrated for 10 days first, and then combination of chemotherapy, carnine and vitamin C was given for 10 days. In BA group, combination of chemotherapy, earnine and vitamin C was administrated for 10 days first, and then combination of chemotherapy and NAC was given for 10 days, a cycle was 21 days. The hepatorenal damage degree was observed and the curative effect of NAC on hepatorenal damage was evaluated. ResultsThere were no differences in the levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST) and serum creatinine(Cr) between pre chemotherapy and post chemotherapy in A cycle[(25.32±5.23) U/L vs. (29.18±5.43) U/L,(29.21±6.51)U/L vs. (32.37±7. 13)U/L, (89.87±19.56)Mmol/L vs. (95.22±20. 60)μmol/L,all P>0. 05] . In B cycle, the levels of ALT,AST and Cr were (56.76±5.53) U/L, (48.83±6.64)U/L and (137.33±21.16)μmol/L post chemotherapy, respectively, which were evidently higher than pre chemotherapy[(26.19 ± 5.51) U/L, (29.95±6.56) U/L and (88.66±18.27)μmol/L,respectively] (all P<0.01) . ConclusionsNAC has better preventive and therapeutic effects on hepatorenal damage caused by the chemotherapeutic drugs in elderly patients with malignant cancer.
